Principal Investigator of the National Cancer Institute-funded Cancer Immunotherapy Trials Network.
Partner laboratory on SX-682 prostate cancer Nature paper. Former President of MD Anderson Cancer Center.
IO thought leader in melanoma. PI of SX-682 Phase I/II melanoma trial.
Leads Wistar’s Translational Tumor Immunology Program. MDSC pioneer and co-investigator in SX-682 melanoma trial.
Expert on tumor microenvironment and host immune response in lung cancer.
Professor and head of the Leukemia and MDS Section at the Moffitt Cancer Center. Principal Investigator of SX-682 MDS Phase I/II trial.
Surgical oncologist focused on breast cancer immunotherapy. Principal Investigator and key design lead of SX-682 Phase I/II breast cancer trial.
Chief of Laboratory of Tumor Immunology and Biology at NCI. Principal Investigator on awarded Syntrix-NCI CRADA to fund SX-682 through Phase II.
Leading expert on treatment and clinical study design in pain clinical trials. Key consultant to company in FDA meetings.
25 years of pharmaceutical industry experience on the discovery and development of novel analgesic drugs.
Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION).
Immuno-oncology pioneer in pancreatic cancer. Principal Investigator of SX-682 Phase I/II pancreatic cancer trial.